文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma.

作者信息

Nierengarten Mary Beth

出版信息

Cancer. 2023 May 15;129(10):1465-1466. doi: 10.1002/cncr.34810.

DOI:10.1002/cncr.34810
PMID:37088993
Abstract
摘要

相似文献

[1]
FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma.

Cancer. 2023-5-15

[2]
Mosunetuzumab: First Approval.

Drugs. 2022-7

[3]
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.

J Hematol Oncol. 2023-6-28

[4]
[Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma].

Bull Cancer. 2022-11

[5]
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Jpn J Clin Oncol. 2023-10-4

[6]
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.

Future Oncol. 2023-10

[7]
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

J Clin Oncol. 2016-2-16

[8]
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.

Lancet Oncol. 2022-8

[9]
Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.

Lancet Oncol. 2022-8

[10]
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.

Clin Lymphoma Myeloma Leuk. 2024-2

引用本文的文献

[1]
Toxicities associated with lymphoma-targeting bispecific antibodies-a review.

Front Med (Lausanne). 2025-7-2

[2]
Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab.

Int J Mol Sci. 2025-1-31

[3]
Bispecific Antibodies for Lymphoid Malignancy Treatment.

Cancers (Basel). 2024-12-31

[4]
Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations.

Patient Prefer Adherence. 2024-10-26

[5]
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

J Immunother Cancer. 2024-3-21

[6]
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.

Pharmacoeconomics. 2024-5

[7]
Bispecific antibodies in indolent B-cell lymphomas.

Front Immunol. 2024-1-11

[8]
Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach.

Cancers (Basel). 2023-9-8

[9]
Considerations for the clinical development of immuno-oncology agents in cancer.

Front Immunol. 2023

[10]
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.

J Hematol Oncol. 2023-6-24

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索